The K65R mutation in HIV-1 reverse transcriptase: Genetic barriers, resistance profile and clinical implications

HIV Therapy

Volumn 3, Issue 6, 2009, Pages 583-594

  Brenner, Bluma G ^a   Coutsinos, Dimitrios ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

HIV 1 drug resistance; K65R; Nucleoside analogs; Subtype C; Tenofovir

Indexed keywords

ABACAVIR; ABACAVIR PLUS DIDANOSINE PLUS TENOFOVIR DISOPROXIL; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIVIRUS AGENT; ARGININE; ARTRIPLA; DIDANOSINE; DIDANOSINE PLUS LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS LAMIVUDINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL PLUS ZIDOVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LYSINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; THYMIDINE DERIVATIVE; UNCLASSIFIED DRUG; ZIDOVUDINE; NUCLEOSIDE ANALOG; VIRUS RNA;

BONE DENSITY; CHRONIC DRUG ADMINISTRATION; CLINICAL ASSESSMENT; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CROSS RESISTANCE; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; NEPHROTOXICITY; NONHUMAN; OSTEOPENIA; OSTEOPOROSIS; REVIEW; RNA STRUCTURE; SIDE EFFECT; TREATMENT PLANNING; VIRUS GENOME; VIRUS MUTATION; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; DEVELOPING COUNTRY; DRUG CONTRAINDICATION; DRUG POTENCY; DRUG SAFETY; DRUG TREATMENT FAILURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; MUTATIONAL ANALYSIS; SINGLE DRUG DOSE;

EID: 70849120990     PISSN: 17584310     EISSN: None     Source Type: Journal    
DOI: 10.2217/hiv.09.40     Document Type: Review

References (89)

1. Riddler SA, Haubrich R, DiRienzo AG: Class-sparing regimens for initial treatment of HIV-1 infection. N. Eng. J. Med. 358(20), 2095-2106 (2008). (Pubitemid 351679596)
2. Petrella M, Oliveira M, Moisi D, Detorio M, Brenner BG, Wainberg MA: Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue culture. Antimicrob. Agents Chemother. 48(11), 4189-4194 (2004).
3. Turner D, Brenner BG, Routy JP, Petrella M, Wainberg MA: Rationale for maintenance of the M184V resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients. New Microbiol. 27(2 Suppl. 1), 31-39 (2004).
4. Cozzi-Lepri A, Ruiz L, Loveday C et al.: Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy. Antivir. Ther. 10(7), 791-802 (2005). (Pubitemid 41652973)
5. Marcelin AG, Delaugerre C, Wirden M et al.: Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J. Med. Virol. 72(1), 162-165 (2004). (Pubitemid 37484758)
6. Johnson VA, Brun-Vézinet F, Clotet B et al.: Update of drug resistance mutations in HIV-1: December 2008. Topics HIV Med. 16(5), 138-145 (2008). □ The International AIDS Society panel meets biannually to discuss resistance mutations associated resistance to the five major drug classes.
7. Miller MD: K65R, TAMs and tenofovir. AIDS Rev. 6(1), 22-33 (2004). □□ Important review detailing the distinct features of thymidine analog mutation (TAM) and K65R resistance pathways.
8. Bartlett JA, Maro VP: Stavudine in first-line antiviral regimens in resource-limited settings; time for a better solution. HIV Ther. 3(2), 109-111 (2009). □□ Compelling editorial raising concerns regarding the use of suboptimal stavudine (d4T) regimens and issues regarding tenofovir disoproxil fumarate (TDF) costs and access in resource-poor settings.
9. Pozniak A: Tenofovir: what have over 1 million years of patient experience taught us? Int. J. Clin. Practice 62(8), 1285-1293 (2008). □□ Summarizes the clinical trials demonstrating the clinical benefit of TDF-based regimens in treatment-naive and treatment-experienced patients.
10. Antinori A, Trotta MP, Lorenzini P et al.: Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation. Antiviral Ther. 12(8), 1175-1183 (2007).
11. Wainberg MA, Miller MD, Quan Y et al.: In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir. Ther. 4, 87-94 (1999). □ First in vitro demonstration of K65R selection with TDF (PMPA).
12. Gu Z, Gao Q, Fang H et al.: Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′- dideoxy- 3′-thiacytidine. Antimicrob. Agents Chemother. 38, 275-281 (1994). □ First identification of K65R resistance in cell-culture selections with didanosine (ddI) and dideoxycytidine.
13. Bazmi HZ, Hammond JL, Cavalcanti SCH et al.: In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-β-d-dioxolane-guanosine and suppress resistance to 3′-azido- 3′-deoxythymidine. Antimicrob. Agents Chemother. 44, 1783-1788 (2000). □□ First study to indicate the potential value of zidovudine to reduce or prevent the selection of K65R.
14. McColl DJ, Chappey C, Parkin NT, Miller MD: Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database. Antivir. Ther. 13(2), 189-197 (2008).
15. van de Vijver DA, Wensing AM, Angarano G et al.: The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J. Acquir. Immune Defic. Syndr. 41(3), 352-360 (2006).
16. Parikh UM, Zalina S, Sluis-Cramer N, Mellors JW: Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase. AIDS 21, 1405-1407 (2007). □□ This landmark study used molecular analysis to show the bidirectional phenotypic antagonism between the K65R and TAM resistance pathways. K65R reduces enzymatic excision of chainterminating nucleoside reverse-transcriptase inhibitor (NRTI) monophosphates (e.g., zidovudine). TAMs counterbalance K65R by decreasing its enzymatic discrimination of d-nucleotide analogs.
17. Parikh UM, Barnas DC, Faruki H, Mellors JW: Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level. J. Infect. Dis. 194, 651-660 (2006). □ Demonstrates genomic counter selection of K65R and TAMs. (Pubitemid 44297851)
18. Frankel FA, Invernizzi CF, Oliveira M, Wainberg MA: Diminished efficiency of HIV-1 reverse transcriptase containing the K65R and M184V drug resistance mutations. AIDS 21, 665-675 (2007). (Pubitemid 46568623)
19. Ly JK, Margot NA, MacArthur HL, Hung M, Miller MD, White KL: The balance between NRTI discrimination and excision drives the susceptibility of HIV-1 RT mutants K65R, M184V and K65R + M184V. Antivir. Chem. Chemother. 18(6), 307-316 (2007).
20. Kagan RM, Lee T-S, Ross É, Lloyd RM, Lewinski MA, Potts SJ: Molecular basis of antagonism between K70E and K65R tenofovir associated mutations in HIV-1 reverse transcriptase. Antivir. Res. 75, 210-218 (2007). □ Demonstrates that the bidirectional antagonism between K65R and K70E is associated with the profound replicative disadvantage of K65R (2.4%) and K65R + K70E (0.01%) versus K70E (97%) and with virus.
21. Waters É, Nelson M, Mandalia S et al.: The risks and incidence of K65R and L74V mutations and subsequent virologic response. Clin. Infect. Dis. 46(1), 96-100 (2008). (Pubitemid 351263566)
22. Svarovskaia ES, Feng J, Margot NA et al.: The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation. J. Acquir. Immune Def. Syndr. 48(1), 428-436 (2008). □ S68G is the only mutation that appears to offset the replicative disadvantage of K65R. Many current genotypic algorithms do not report this compensatory mutation.
23. Van Laethem K, Pannecouque C, Vandamme AM: Mutations at 65 and 70 within the context of a Q151M cluster in human immunodeficiency virus type 1 reverse transcriptase impact the susceptibility to the different nucleoside reverse transcriptase inhibitors in dzistinct ways. Infect. Genet. Evol. 7(5), 600-603 (2007). (Pubitemid 47338288)
24. Boucher S, Recordon-Pinson P, Ragnaud JM, Dupon M, Fleury H, Masquelier B: HIV-1 reverse transcriptase (RT) genotypic patterns and treatment characteristics associated with the K65R RT mutation. HIV Med. 7(5), 294-298 (2006). (Pubitemid 43805689)
25. Trotta MP, Bonfigli S, Ceccherini-Silberstein F: Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir. J. Med. Virol. 78(5), 535-541 (2006).
26. Feng JY, Myrick FT, Margot NA et al.: Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine. Nucleosides Nucleotides Nucleic Acids 25(1), 89-107 (2006).
27. Trignetti M, Sing T, Svicher V et al.: Dynamics of NRTI resistance mutations during therapy interruption. AIDS Res. Hum. Retroviruses 25(1), 57-64 (2009). □□ The rapid disappearance of K65R relative to other NRTI mutations upon treatment interruption is a clinical indication of its impaired replicative capacity.
28. Saag MS: Perspective. Initiation of antiretroviral therapy: implications of recent findings. Topics HIV Med. 12(3), 83-88 (2004).
29. Gallant JE, Rodriguez AE, Weinberg W et al.: Early virologic non-response to tenofovir, abacavir and lamivudine in HIV-infected antiretroviral-naive subjects. J. Infect. Dis. 192, 1921-1930 (2005). □ First study to report the rapid selection of K65R with triple nucleoside analogs. This strategy has been discontinued.
30. Martin-Carboner É, Gil P, Garcia-Benayas TG et al.: Rate of virologic failure and selection of drug resistance mutations using different triple nucleos(t)ide analogue combinations in HIV-infected patients. AIDS Res. Hum. Retroviruses 22(12), 1231-1235 (2006). (Pubitemid 46095239)
31. Gillam BL, Sajadi MM, Amoroso A, Davis CE, Cleghorn FR, Redfield RR: Tenofovir and abacavir combination therapy: lessons learned from an urban clinic population. AIDS Patient Care STDs 21(4), 240-245 (2007). (Pubitemid 46676678)
32. Delaunay C, Brun-Vézinat F, Landman R et al.: Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021). J. Virol. 79(15), 9572-9578 (2005). □ Demonstrates genomic antagonism of K65R and M184V leading to treatment failure.
33. Underwood MR, Ross LI, Irlbeck DM et al.: Sensitivity of phenotypic susceptibility analyses for non-thymidine nucleoside analogs conferred by K65R or M184V in mixtures with wild type HIV-1. J. Infect. Dis. 199, 84-88 (2009). □ Demonstrates how K65K/R and M184M/ I/V mixtures can underestimate phenotypic resistance to NRTIs.
34. Ntemgwa ML, Toni T, Brenner BG et al.: Nucleoside and nucleotide analogs select in culture for different patterns of drug resistance in human immunodeficiency virus types 1 and 2. Antimicrob. Agents Chemother. 53(2), 708-715 (2009).
35. Metzner KJ, Giulieri SG, Knoerfel SA et al.: Minority quasispecies of drug resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. Clin. Infect. Dis. 48, 239-247 (2009).
36. Svarovskaia ES, Margot NA, Bae AS et al.: Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine. J. Acquir. Immune Defic. Syndr. 46(2), 174-180, (2007).
37. Lanier ER, Givens N, Stone C et al.: Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens. HIV Med. 5(6), 394-399 (2004). (Pubitemid 39549364)
38. Ross L, Elion R, Lanier R et al.: Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (Study COL40263). AIDS Res. Hum. Retroviruses 25(7), 665-672 (2009).
39. Ait-Khaled M, Rakik A, Griffin P et al.: Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy. Antivir. Ther. 7(1), 43-51(2002). (Pubitemid 36285551)
40. Gallant JE, Staszewski S, Pozniak AL et al.: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292(2), 191-201 (2004). (Pubitemid 38917996)
41. Khanlou H, Yeh V, Guyer B, Farthing C: AIDS Patient Care STDS 9(3), 135-140 (2005).
42. Miller MD, Margot NA, McColl DJ et al.: Characteristics of resistance mutation patterns emerging over 2 years during first-line antiretroviral treatment with tenofovir DF or stavudine in combination with lamivudine and efavirenz. Antivir. Ther. 8, S151 (2003).
43. Roge BT, Katzenstein TL, Obel N et al.: K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Antivir. Ther. 8, 173-182 (2003). (Pubitemid 36565898)
44. Jemsek J, Hutcherson P, Harper E: Poor virologic responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF. Presented at: 11th Conference on Retroviruses and Opportunisistic Infections. San Francisco, CA, USA, 8-11 February 2004 (Abstract 42).
45. Gulick RM, Ribaudo HJ, Shikuma CM et al.: Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N. Engl. J. Med. 350, 1850-1861 (2004).
46. Elion R, Cohen C, DeJesus E et al.: COL40263: resistance and efficacy of once-daily trizivir and tenofovir DF in antiretroviral-naive subjects. Presented at: 11th Conference on Retroviruses and Opportunisistic Infections. San Francisco, CA, USA, 8-11 February 2004 (Abstract 53).
47. Theys K, Vercauteren J, Abecasis AA et al.: The rise and fall of K65R in a Portugese HIV-1 drug resistance database, despite continuing use of tenofovir. Infect. Genet. Evol. 4(9), 683-688 (2009).
48. de Mendoza C, Jimenez-Nacher I, Garrido C et al.: Changing patterns in HIV reverse transcripase mutations after the availability of tenofovir. Clin. Infect. Dis. 46, 1782-1785 (2008). (Pubitemid 351706779)
49. + cell count.
50. Rey D, Hoen B, Chavanet P et al.: High rate of early virological failure with the once daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. J. Antimicrob. Chemother. 63, 380-388 (2009).
51. Clotet B. Once daily dosing of nevirapine in HAART. J. Antimicrob. Chemother. 61, 13-16 (2008). □ The DAUFIN trial showed unexpected high rate of K65R with once-daily TDF/lamivudine (3TC)/nevirapine (NVP).
52. Deforche K, Camacho RJ, Grossman Z et al.: Bayesian network analysis of resistance analysis of resistance pathways against efavirenz and nevirapine. AIDS 22, 2107-2115 (2008). □ The non-B HIV Working Group is involved in ascertaining the role of subtype diversity in HIV resistance. There is an association between non-B subtype and K65R resistance. Pooled analysis of all non-B subtypes and restrictions to amino acid, rather than nucleotide diversity may, however, fail to adequately define the role of subtype diversity in the selection of resistance mutations.
53. Llibre JM, Bonjoch A, Iribarren J et al.: Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study. HIV Med. 9, 508-513 (2008). □ A promising salvage strategy to bridge K65R and TAM resistance in patients harboring multidrug resistance.
54. Ferrer E, Gatell J, Sanchez P et al.: Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96 week prospective one-arm pilot study. AIDS Res. Hum. Retroviruses 24(7), 931-934 (2008). □ An intriguing future strategy for NRTI/non- NRTI/protease inhibitor-sparing regimens for long-term HIV-1 management, based on the bidirectional antagonism between K65R and TAM pathways.
55. Hurwitz SJ, Asif G, Kivel NM, Schinazi RF: Development of an optimized dose for coformulation of zidovudine with drugs that select for the K65R mutation using a population pharmacokinetic and enzyme kinetic simulation model. Antimicrob. Agents Chemother. 52, 4241-4250 (2008).
56. Brenner BG: Resistance and viral subtypes. How important are the differences and why do they occur? Curr. Opin. HIV AIDS 2, 94-102 (2007).
57. Kantor R, Katzenstein DA, Efron B et al.: Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2(e112), 325-337 (2005). □ This international collaborative team has been established to compile non-B subtypes sequences from different geographic regions.
58. Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM: The challenge of HIV-1 subtype diversity. N. Engl. J. Med. 358 (15), 1590-1602 (2009).
59. Geretti AM: HIV subtypes: epidemiology and significance for HIV management. Curr. Opin. Infect. Dis. 19, 1-7 (2006).
60. Martinez-Cajas JL, Pant-Pai N, Klein M, Wainberg MA: Role of genetic diversity amongst non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence. AIDS Rev. 10, 12-23 (2008). □ Summarizes clinical and cell culture data of subtype differences in emergent resistance to antiretroviral therapy.
61. Ntemgwa ML, Toni TD, Brenner BG, Camacho RJ, Wainberg MA: Antiretroviral drug resistance in human immunodeficiency virus type-2 (HIV-2). Antimicrob. Agents Chemother. doi: 10.1128/AAC.00154-09 (2009) (Epub ahead of print).
62. Smith RA, Anderson DJ, Pyrak CL, Preston BD, Gottlieb GS: Antiretroviral drug resistance in HIV-2: three amino acid changes are sufficient for classwide nucleoside analogue resistance. J. Infect. Dis. 199, 1323-1326 (2009).
63. Gottlieb GS, Badiane NM, Hawkes S et al.: Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resource limited West Africa. Clin. Infect. Dis. 48, 476-483 (2009).
64. Doualla-Bell F, Avalos A, Brenner B et al.: High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob. Agents Chemother. 50(12), 4182-4185 (2006). □□ Among the earliest studies to demonstrate the accelerated development of K65R in subtype C infections. It led to studies characterizing the molecular basis for the facilitated development of K65R in subtype C.
65. Brenner BG, Oliveira M, Doualla-Bell F et al.: HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 20(9), F9-F13 (2006). □□ Landmark study using a cell-culture selection approach to demonstrate the accelerated development of K65R in subtype C. Follow-up studies have combined site-directed mutagenesis and enzymatic studies to mechanistically define the molecular basis for facilitated development of K65R in subtype C [72-74]. This has important clinical implications in K65R development using 'less forgiving' suboptimal d4T and ddI regimens in third-world settings.
66. Miller MD, Margot N, McColl D, Cheng AK: K65R development among subtype C HIV-1 patients in tenofovir DF clinical trials. AIDS 21, 265-266 (2007). □ While these authors argued against the findings of a previous reference [65], clinical studies clearly demonstrate the facilitated development of K65R in resource-poor settings with d4T-NVP and d4T-ddI. However, the potency of TDF/emtricitabine regimens may offset the development of K65R in subtype C.
67. Sungkanuparph, S, Manosuthi W, Kiertiburanakul S, Saekang N, Pairoj W, Chantratita W: Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine. J. Clin. Virol. 41(4), 310-313 (2008).
68. Hosseinipour M, van Oosterhout JJ, Weigel R et al.: The public health approach to identify antiretroviral therapy failure: high level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 23, 1127-1134 (2009). □□ Important study demonstrating clinical correlates for the disparate high rates of K65R in subtype C viruses failing d4T/3TC/NVP regimens in Malawi.
69. Pillay V, Pillay C, Kantor R, Venter F, Levin É, Morris L: HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. AIDS Res. Hum. Retroviruses 24(11), 1449-1454 (2008).
70. Coutsinos D, Invernizzi CF, Xu H et al.: Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1. J. Virol. 83(4), 2029-2033 (2009). □□ Important enzymatic study, summarized in Figure 2, which illustrates the mechanism for accelerated development of K65R in subtype C.
71. Invernizzi CF, Coutsinos D, Moisi D et al.: Introduction of the 64/65 nucleotide polymorphisms of subtype C into subtype B HIV-1 selects for the K65R mutational pathway in cell culture. Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 3-6 February 2008 (Poster 849). □□ An important paper using site-directed mutagenesis of two nucleotides in codons 64 and 65 of subtype B to demonstrate the template-based mechanism for the facilitated selection of K65R in subtype C infections.
72. Invernizzi C, Oliveira M, Moisi D, Brenner B, Wainberg M: Preferred K65R pathway in subtype C HIV-1 can be altered by silent polymorphisms at thymidine analogue mutation sites in cell culture drug selections. Presented at: 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, 16-20 February 2009 (Poster 628).
73. Xu HT, Martinez-Cajas JL, Ntemgwa ML et al.: Effects of the K65R and K65R/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance. Retrovirology 6, 14-25 (2009).
74. Dobard C, Lipscomb J, Johnson JA, Garcia-Lerma JG, Heneine W: Recombinant viruses expressing subtype B or subtype C reverse transcriptase reveal no difference in the rate of K65R resistance to tenofovir in cell culture. Antivir. Ther. 14(Suppl. 1), A23 (2009). □ Recombinant viruses expressing subtype B or subtype C reverse transcriptase revealed no differences in subtype B and C enzymatic activity. This study failed to observe differences in the emergence times of K65R resistance with TDF in MT-4 cells. The rapid selection times for HXB2 viruses in MT-4 cell lines may have masked subtype B and C differences. It should be noted that subtype C clinical isolates are primarily R5-tropic and do not grow in MT-2 and MT-4 cells.
75. Bebenek K, Abbotts J, Wilson SH, Kunkel TA: Error-prone polymerization by HIV-1 reverse transcriptase. Contribution of template-primer misalignment, miscoding, and termination probability to mutational hot spots. J. Biol. Chem. 268(14), 10324-10334 (1993). (Pubitemid 23150215)
76. Buiser RG, Bambara RA, Fay PJ: Pausing by retroviral DNA polymerases promotes strand transfer from internal regions of RNA donor templates to homopolymeric acceptor templates. Biochim. Biophys. Acta 1216(1), 20-30 (1993).
77. Hu WS, Temin HM: Retroviral recombination and reverse transcription. Science 250(4985), 1227-1233 (1990).
78. Huber HE, McCoy JM, Seehra JS, Richardson CC: Human immunodeficiency virus 1 reverse transcriptase. Template binding, processivity, strand displacement synthesis, and template switching. J. Biol. Chem. 264(8), 4669-4678 (1989).
79. Klarmann GJ, Schauber CA, Preston BD: Template-directed pausing of DNA synthesis by HIV-1 reverse transcriptase during polymerization of HIV-1 sequences in vitro. J. Biol. Chem. 268(13), 9793-9802 (1993).
80. Schinazi RF, Lloyd RM, Ramanathan CS, Taylor EW: Antiviral drug resistance mutations in HIV-1 reverse transcriptase occur in specific RNA structural regions. Antimicrob. Agents Chemother. 38, 268-274 (1994). □□ Frst paper to show that antiviral drug-resistance mutations in HIV-1 reverse transcriptase occur in specific RNA structural regions. This has implications in the facilitated selection of K65R in subtype C.
81. Steegen K, Luchters S, Dauwe K et al.: Effectiveness of antiretroviral therapy and development of drug resistance in HIV-infected patients in Mombasa, Kenya. AIDS Res. Ther. 6, 12 (2009).
82. Andrew R, Stöhr W, Walker S et al.: Severe renal dysfunction and risk factors associated with renal impairment in HIV-Infected adults in Africa initiating antiretroviral therapy. Clin. Infect. Dis. 46, 1271-1281 (2008). (Pubitemid 351589914)
83. García-Lerma JG, Otten RA, Qari SH et al.: Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLos Med. 5(2), e28 (2008).
84. Paltiel AD, Freedberg KA, Scott CA et al.: HIV pre-exposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin. Infect. Dis. 48(6), 806-815 (2009).
85. Okwundu CI, Okoromah CA: Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. Cochrane Database Syst. Rev. 21(1), 1-11 (2009).
86. Lidstrom J, Kumwenda N, Kafulafula G et al.: Antiretroviral treatment of HIV-infected women can induce multiclass drug resistance in their breastfeeding infants. Antivir. Ther. 14(Suppl. 1), A158 (2009). □ Demonstrates the transmission of K65R to four out of four infants through breastfeeding.
87. Foster C, Lyall H, Olmscheiid B et al.: Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? HIV Med. 10(7), 397-406 (2009). □□ Important article with respect to the potential benedit of TDF and TDF/3TC in preventing mother-child transmission.
88. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 3 November, 1-139 (2008). www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. □ The Department of Health and Human Services guidelines for HIV-1 treatment are updated regularly. TDF/FTC and TDF/3TC are the NRTI regimens of choice to be used in treatment-naive and experienced patients. ABC/3TC were also recommended until recent students of increased risk of cardiac implications.
89. Stanford University HIV drug resistance database. http://hivdb.stanford. edu □□ Openly available and frequently updated database allows researchers and clinicians alike to determine the incidence of drug resistance mutations and genotypic-phenotypic correlations for resistance, treatments and subtypes.